🔎 Trials Near Me

Home › NCT07698197

Exercise Intervention and Immunodeficiency

Recruiting

Exercise Intervention in Primary Antibody Deficiency Disorders: A 12-week Feasibility Study

Who can join

Ages 18 to 65 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Diagnosed with one of the following primary antibody deficiencies: IgG subclass deficiency, selective IgA deficiency, selective IgM deficiency, or specific antibody deficiency
* Receiving care in the Section of Rheumatology, Allergy \& Immunology
* Able and willing to participate in a moderate-intensity exercise program. Patients will be screened using the American College of Sports Medicine (ACSM) Pre- participation Screening Guidelines. This algorithm assesses patients for cardiovascular, renal, and metabolic disease. Those patients determined to not require further medical clearance to participate in exercise will be included.

Exclusion Criteria:

* Receipt of immunoglobulin (Ig) replacement therapy
* Use of immunosuppressive or immunomodulatory medications (e.g., chronic systemic corticosteroids, B-cell-depleting therapies)
* Medical contraindications to moderate-intensity exercise as determined by clinical assessment using the previously discussed ACSM Pre-participation Screening Guidelines.
* Other risk factors/medical conditions that would limit safe participation in exercise as determined by clinical assessment, including active rheumatologic conditions including active rheumatoid arthritis.

About the study

The purpose of this study is to assess if a 12-week exercise program is safe, practical, and acceptable for adults with primary antibody deficiencies. It also looks at whether the program can improve the quality of life and help the immune system work better.

What is being tested

Sponsor: Yale University · Participants: 20 · Started: Jul 17, 2026

Contact the study team

Official record on ClinicalTrials.gov — NCT07698197

Locations in the U.S.

ConnecticutBridgeport Hospital, Milford
Yale New Haven Health, North Haven

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.